advertisement

WGC-2021

11.3 Adrenergic drugs (5)

Showing records 1 to 5

Display only abstracts from IGR 20-4 in classification 11.3 Adrenergic drugs

Search within classification 11.3 Adrenergic drugs

82353 Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019)
Nocentini A; Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 805-815 (IGR: 20-4)


20828 Effect on Diurnal Intraocular Pressure Variation of Eliminating the α-2 Adrenergic Receptor Subtypes in the Mouse
Aihara M; Lindsey JD; Weinreb RN
Investigative Ophthalmology and Visual Science 2008; 49: 929-933 (IGR: 10-1)


13425 Topical ibopamine in the treatment of chronic ocular hypotony attributable to vitreoretinal surgery, uveitis, or penetrating trauma
Ugahary LC; Ganteris E; Veckeneer M; Cohen AC; Jansen J; Mulder PG; van Meurs JC
American Journal of Ophthalmology 2006; 141: 571-573 (IGR: 8-1)


8740 Comparative study of the effects of 2% ibopamine, 10% phenylephrine, and 1% tropicamide on the anterior segment
Marchini G; Babighian S; Tosi R; Perfetti S; Bonomi L
Investigative Ophthalmology and Visual Science 2003; 44: 281-289 (IGR: 5-1)


6825 Effects of topical antiglaucoma eye drops on prostaglandin E2-induced aqueous flare elevation in pigmented rabbits
Hayasaka Y; Hayasaka S; Zhang XY; Nagaki Y
Investigative Ophthalmology and Visual Science 2002; 43: 1142-1145 (IGR: 4-1)



Issue 20-4

Select Issue


advertisement

Oculus